利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.014 秒)

    Inhibited expression of PD-L1 and enhanced expression of PD-1
    1.
    发明授权
    Inhibited expression of PD-L1 and enhanced expression of PD-1 有权

    公开(公告)号：US10478418B2

    公开(公告)日：2019-11-19

    申请号：US16128786

    申请日：2018-09-12

    申请人： IN Ingredients, Inc.

    发明人： Augustin T. Romero ,  Bolin Qin

    IPC分类号： A61K36/00 ,  A61K31/357 ,  A61K36/53 ,  A61K36/9066 ,  A61K36/63 ,  A61K36/73 ,  A61K31/353 ,  A61K31/7048 ,  A61K36/49 ,  A61K9/00

    摘要： Processes for decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of cinnamtannin D-1 and/or cinnamtannin B-1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in the subject by the step of administering at the desired concentration or for the desired time wherein the composition may increase or decrease the relative expression levels of the genes or proteins while simultaneously ameliorating, preventing, or modulating a cardiac event in the subject.

    INHIBITED EXPRESSION OF PD-L1 AND ENHANCED EXPRESSION OF PD-1
    3.
    发明申请
    INHIBITED EXPRESSION OF PD-L1 AND ENHANCED EXPRESSION OF PD-1 审中-公开

    公开(公告)号：US20200054597A1

    公开(公告)日：2020-02-20

    申请号：US16653308

    申请日：2019-10-15

    申请人： IN Ingredients, Inc.

    发明人： Augustin Romero ,  Bolin Qin

    IPC分类号： A61K31/357 ,  A61K36/49 ,  A61K31/7048 ,  A61K31/353 ,  A61K36/73 ,  A61K36/63 ,  A61K36/9066 ,  A61K36/53 ,  A61K36/54

    摘要： Processes for treating an autoimmune disease or condition by decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of cinnamtannin D-1 and/or cinnamtannin B-1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein and increasing expression of a PDCD1 gene and/or a PD-1 protein in the subject by the step of administering at the desired concentration or for the desired time wherein the composition may increase or decrease the relative expression levels of the genes or proteins while simultaneously ameliorating, preventing, or modulating a cardiac event in the subject.

    Methods and Compositions for the Inhibition of the Expression of PD-L1 in Tumor Cells
    4.
    发明申请
    Methods and Compositions for the Inhibition of the Expression of PD-L1 in Tumor Cells 审中-公开

    公开(公告)号：US20190076393A1

    公开(公告)日：2019-03-14

    申请号：US15703165

    申请日：2017-09-13

    申请人： IN Ingredients, Inc.

    发明人： Augustin T. Romero ,  Bolin Qin

    IPC分类号： A61K31/353

    摘要： Processes for decreasing expression of a CD274 gene and/or a PD-L1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of an active ingredient by weight. The active ingredient includes cinnamtannin D1 and/or cinnamtannin B1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein in the subject by the step of administering.

    ENHANCED EXPRESSION OF mTOR AND INHIBITED EXPRESSION OF MYOSTATIN IN SKELETAL MUSCLE CELLS
    5.
    发明申请
    ENHANCED EXPRESSION OF mTOR AND INHIBITED EXPRESSION OF MYOSTATIN IN SKELETAL MUSCLE CELLS 审中-公开

    公开(公告)号：US20180296522A1

    公开(公告)日：2018-10-18

    申请号：US15524742

    申请日：2015-11-06

    申请人： IN Ingredients, Inc.

    发明人： Bolin Qin ,  Augustin T. Romero

    IPC分类号： A61K31/353 ,  A61K9/00 ,  A61K45/06 ,  G01N33/68 ,  C12Q1/6876

    摘要： Processes for increasing expression of a MTOR gene or a mTOR protein or decreasing expression of a MSTN gene or a myostatin protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% Type-A polymers by weight. The Type-A polymers include A-Type doubly-linked procyanidin oligomers of the catechins and/or epicatechins. The processes further include increasing expression of a MTOR gene or a mTOR protein or decreasing expression of a MSTN gene or a myostatin protein in the subject by the step of administering.

    COMPOSITIONS AND METHODS FOR THE TREATMENT OR PROPHYLAXIS OF CIRCADIAN PROTEIN RELATED CONDITIONS
    7.
    发明申请
    COMPOSITIONS AND METHODS FOR THE TREATMENT OR PROPHYLAXIS OF CIRCADIAN PROTEIN RELATED CONDITIONS 审中-公开
    用于治疗或预防血浆蛋白相关病症的组合物和方法

    公开(公告)号：US20160256511A1

    公开(公告)日：2016-09-08

    申请号：US14431097

    申请日：2014-11-13

    申请人： IN INGREDIENTS, INC.

    发明人： Bolin Qin ,  Augustin T. Romero ,  Tim Romero

    IPC分类号： A61K36/88 ,  A61K31/56 ,  A61K36/53

    CPC分类号： A61K36/53 ,  A23K20/10 ,  A23K20/105 ,  A23K20/158 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/19 ,  A61K31/56 ,  A61K36/88 ,  A61K36/896 ,  A61K2236/331 ,  A61K2300/00

    摘要： Provided are compositions and processes of treating or preventing one or more conditions related to a protein involved in circadian rhythm. A composition includes an extract of rosemary, an extract of hemerocallis fulva, active portion or component thereof, or combinations thereof, optionally provided as a component of a dietary supplement. The presence of one or more active ingredients in the extracts optionally administered at a targeted administration time alters the expression of one or more genes or proteins involved in circadian rhythm, illustratively CLOCK, BMAL1, FBXL3, FBXL21, or SIRT1.

    摘要翻译： 提供了治疗或预防与涉及昼夜节律的蛋白质相关的一种或多种病症的组合物和方法。 组合物包含迷迭香提取物，半乳聚糖的提取物，活性部分或其组分或其组合，任选地作为膳食补充剂的组分提供。 任选地在目标给药时间施用的提取物中存在一种或多种活性成分改变参与昼夜节律的一种或多种基因或蛋白质的表达，例如CLOCK，BMAL1，FBXL3，FBXL21或SIRT1。

    Methods and compositions for the inhibition of the expression of PD-L1 in tumor cells
    8.
    发明授权
    Methods and compositions for the inhibition of the expression of PD-L1 in tumor cells 有权

    公开(公告)号：US10894030B2

    公开(公告)日：2021-01-19

    申请号：US15703165

    申请日：2017-09-13

    申请人： IN Ingredients, Inc.

    发明人： Augustin T. Romero ,  Bolin Qin

    IPC分类号： A61K31/353

    摘要： Processes for decreasing expression of a CD274 gene and/or a PD-L1 protein in a subject in need of such expression changes are provided. The processes include administering to the subject a composition including at least 0.5% of an active ingredient by weight. The active ingredient includes cinnamtannin D1 and/or cinnamtannin B1. The processes further include decreasing expression of a CD274 gene and/or a PD-L1 protein in the subject by the step of administering.